Aprepitant Suppliers & Bulk Manufacturers

Available Forms: Oral capsules, Injection (IV)

Available Strengths: Capsule (80 mg, 125 mg); Injection (IV):150 mg/3 mL

Reference Brands: Emend®(US & EU)

Category: Oncology Cancer Care

Aprepitant is available in Oral capsules, Injection (IV) and strengths such as Capsule (80 mg, 125 mg); Injection (IV):150 mg/3 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Aprepitant is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Aprepitant can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Aprepitant 80 mg and 125 mg Capsules are essential in managing chemotherapy-induced nausea and vomiting (CINV). Available under the brand name Emend® in both oral capsule and intravenous injection (150 mg/3 mL) formulations, Aprepitant is a neurokinin-1 receptor antagonist used in combination with other antiemetic agents. Approved in both the U.S. and EU, it effectively prevents acute and delayed nausea and vomiting caused by chemotherapy treatments, particularly those with high emetogenic potential. Aprepitant plays a critical role in oncology B2B portfolios focused on supportive cancer care, improving patient quality of life during treatment.